Adaptive Biotechnologies Corp

Following a strong Stage 2 advance, ADPT is pulling back into rising 9EMA/20EMA support after an extended rally. Although a Bullish Exhaustion pattern warns of waning upside momentum, price remains above key moving averages and within a bullish medium-term structure. Execution now via a pullback interaction aligns with our HMOM momentum-oriented strategy, while respect for the EMAs and support zones manages risk for a continued advance.

• ↑Q2 2026 revenue reached $71.6M, up 30% YoY, led by a 49% MRD surge
• ↑Adjusted EBITDA jumped to $9.1M from $1.9M YoY, boosting operating margins
• ↓Net loss of $39.9M in Q2 intensifies cash-burn and funding risks